RAF1 and cardiac hypertrophy: Beneficial effects of sorafenib on RV remodeling/dysfunction were attributed to the inhibition of Raf/MEK/ERK pathway [10], where ERK activation has been previously shown to be involved in the development of T4-induced cardiac hypertrophy [15].